-
1.发明申请ISOINDOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权ISOINDOLINE衍生物，含有它们的药物组合物及其在治疗中的使用公开(公告)号：US20130210880A1
公开(公告)日：2013-08-15
申请号：US13764454
申请日：2013-02-11
发明人： Wilhelm Amberg , Udo LANGE , Michael OCHSE , Frauke POHLKI , Charles W. HUTCHINS , Irini ZANZE , Hongyu H. ZHAO , Huan-Qiu LI , Ying X. WANG
IPC分类号： C07D209/46 , C07D405/14 , C07D403/12
CPC分类号： C07D209/46 , C07D209/44 , C07D403/12 , C07D405/14
摘要： The present invention relates to isoindoline derivatives of the formula (I) or a physiologically tolerated salt thereof.The present invention also relates to pharmaceutical compositions comprising such isoindoline derivatives, and the use of such isoindoline derivatives for therapeutic purposes.
摘要翻译： 本发明涉及式（I）的异二氢吲哚衍生物或其生理耐受盐。 本发明还涉及包含这种异二氢吲哚衍生物的药物组合物，以及用于治疗目的的这种异吲哚啉衍生物的用途。
-
公开(公告)号：US20180105530A1
公开(公告)日：2018-04-19
申请号：US15793711
申请日：2017-10-25
发明人： Ramin FAGHIH , Achim MOELLER , Michael OCHSE , Frauke POHLKI , Martin SCHMIDT , Kevin SIPPY , Sean TURNER , Elizabeth Louise VAN DER KAM
IPC分类号： C07D487/04 , C07D519/00
CPC分类号： C07D487/04 , A61K31/519 , C07D519/00
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
-
公开(公告)号：US20200239494A1
公开(公告)日：2020-07-30
申请号：US16639555
申请日：2018-08-15
发明人： Wilfried BRAJE , George DOHERTY , Katja JANTOS , Cheng JI , Andrew JUDD , Aaron KUNZER , Anthony MASTRACCHIO , Xiaohong SONG , Andrew SOUERS , Gerard SULLIVAN , Zhi-Fu TAO , Chunqiu LAI , Andreas KLING , Frauke POHLKI , Jesse TESKE , Michael WENDT , Patrick BRADY , Xilu WANG , Thomas PENNING , Michael Michaelides
IPC分类号： C07D495/16 , C07D519/00 , A61P35/00
摘要： The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
公开(公告)号：US20160304527A1
公开(公告)日：2016-10-20
申请号：US15133851
申请日：2016-04-20
发明人： Ramin FAGHIH , Achim MOELLER , Michael OCHSE , Frauke POHLKI , Martin SCHMIDT , Michael SCHULZ , Kevin SIPPY , Sean TURNER , Elizabeth Louise VAN DER KAM
IPC分类号： C07D487/04 , C07D519/00
CPC分类号： C07D487/04 , A61K31/519 , C07D519/00
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.
摘要翻译： 其中R 1，R 2，R 3，R 4，L 1和G 1如说明书中所定义，可用于治疗通过γ-氨基丁酸B（GABA）的正性变构调节来预防或改善的病症或病症， B）受体。 描述了制备化合物的方法。 还描述了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。
-
5.发明申请N-SUBSTITUTED AMINOBENZOCYCLOHEPTENE, AMINOTETRALINE, AMINOINDANE AND PHENALKYLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY 有权N-取代的氨基苯甲酸，氨基嘌呤，氨基丁酸和苯丙氨酸衍生物，含有它们的药物组合物及其在治疗中的使用公开(公告)号：US20130131132A1
公开(公告)日：2013-05-23
申请号：US13680488
申请日：2012-11-19
IPC分类号： C07D403/12 , C07D305/08
CPC分类号： C07D403/12 , C07D233/84 , C07D305/08
摘要： The present invention relates to N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives of the formula (I), (II), (III) or (IV) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, and the use of such N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives for therapeutic purposes. The N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives are GlyT1 inhibitors.
摘要翻译： 本发明涉及式（I），（II），（III）或（IV）的N-取代氨基苯并环庚三烯，氨基三氢化萘，氨基茚满和苯烷基胺衍生物或其生理上耐受的盐。 本发明涉及包含这种N-取代的氨基苯并环庚烯，氨基四氢化萘，氨基茚满和苯烷基胺衍生物的药物组合物，以及用于治疗目的的这种N-取代氨基苯并环庚烯，氨基四氢化萘，氨基茚满和苯烷基胺衍生物的用途。 N-取代的氨基苯并环庚三烯，氨基四氢化萘，氨基茚满和苯烷基胺衍生物是GlyT1抑制剂。
-
公开(公告)号：US20200255451A1
公开(公告)日：2020-08-13
申请号：US16639560
申请日：2018-08-15
发明人： Wilfried BRAJE , George DOHERTY , Katja JANTOS , Cheng JI , Andrew JUDD , Aaron KUNZER , Anthony MASTRACCHIO , Xiaohong SONG , Andrew SOUERS , Gerard SULLIVAN , Zhi-Fu TAO , Chunqiu LAI , Andreas KLING , Frauke POHLKI , Jesse TESKE , Michael WENDT , Patrick BRADY , Xilu WANG , Thomas PENNING , Yujia DAI , Jane GONG , Roberto RISI , Yiyun YU , Guidong ZHU , Dominique POTIN , Fabrice Guillier
IPC分类号： C07D498/16 , C07D491/16 , C07D495/16 , C07D519/00 , A61P35/00
摘要： The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
-
7.发明申请公开(公告)号：US20170260158A1
公开(公告)日：2017-09-14
申请号：US15458534
申请日：2017-03-14
发明人： Hervé GENESTE , Andreas HAUPT , Frauke POHLKI , Ana Lucia RELO , Liliane UNGER , Karsten WICKE
IPC分类号： C07D401/04 , C07D401/14
CPC分类号： C07D401/04 , C07D401/12 , C07D401/14
摘要： The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.
-
8.发明申请公开(公告)号：US20190135777A1
公开(公告)日：2019-05-09
申请号：US16229723
申请日：2018-12-21
发明人： Hervé GENESTE , Andreas HAUPT , Frauke POHLKI , Ana Lucia RELO , Liliane UNGER , Karsten WICKE
IPC分类号： C07D401/04 , C07D401/12 , C07D401/14
摘要： The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT6 receptor.
-
公开(公告)号：US20190062305A1
公开(公告)日：2019-02-28
申请号：US15761735
申请日：2016-09-21
发明人： Gisela BACKFISCH , Margaretha BAKKER , Günter BLAICH , Wilfried BRAJE , Karla DRESCHER , Thomas ERHARD , Andreas HAUPT , Carolin HOFT , Andreas KLING , Viktor LAKICS , Helmut MACK , Frank OELLIEN , Raimund PETER , Frauke POHLKI , Ana Lucia RELO
IPC分类号： C07D401/12 , C07D401/14
摘要： The present invention relates to pyridyl or pyrazinyl compounds carrying a methyl-bound N-amide moiety derived from an α-amino acid of formula I where the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, and to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT2C receptor.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.024 秒)
